Placebo-controlled clinical trials: how trial documents justify the use of randomisation and placebo

BMC Medical Ethics

Anna-Maija Pietilä³  Emmi Itkonen¹  Arja Halkoaho¹  Tapani Keränen² 

[1] Science Service Center, Kuopio University Hospital, P.O. Box 100, Kuopio 70029 KYS, Finland;National Institute for Health and Welfare, Mannerheimintie 170, P.O. Box 30, 00271 Helsinki, Finland;Department of Nursing, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland

关键词: Justification;    Ethics;    Randomisation;    Placebo;    Clinical trials;   

Others  :  1089922
DOI  :  10.1186/1472-6939-16-2

 received in 2014-05-19, accepted in 2015-01-05,  发布年份 2015

【 摘 要 】

Background

Randomised clinical trials (RCTs) involve procedures such as randomisation, blinding, and placebo use, which are not part of standard medical care. Patients asked to participate in RCTs often experience difficulties in understanding the meaning of these and their justification.

Methods

We reviewed RCT protocols, statements of the principal investigator (PI), and participant-information materials, as submitted for opinion to a research ethics committee. We evaluated how the justification for the use of placebo was described in these documents and how the participants had been informed about randomisation, placebo use, and the possible risks of receiving placebo.

Results

In total, 52 RCTs were identified. Eighteen of the study protocols (35%) provided some rationale for the use of placebo. In 15 (29%) of the statements, the PI had provided justification for its use. Possible risks related to placebo use were described in nine (17%) of the statements. An explanation as to why placebo was necessary featured in only 12 (23%) of the sets of participant-information materials, and only six (12%) of the documents discussed the possible risks associated with placebo.

Conclusions

The justification of placebo control was inadequately described in the RCT study protocols, by principal or national co-ordinating investigators, and in participant-information documents. Furthermore, possible health-related risks associated with the use of placebo were poorly explained in the participant-information documents. Ethics committes and study participants need to be better informed of the rationale for the use of placebo, along with the associated risks.

【 授权许可】

   
2015 Keränen et al.; licensee BioMed Central.

【 参考文献 】

• [1]Verheggen FW, Jonkers R, Kok G: Patients’ perceptions on informed consent and the quality of information disclosure in clinical trials. Patient Educ Couns 1996, 29:137-53.
• [2]Featherstone K, Donovan JL: Random allocation or allocation at random? Patients’ perspectives of participation in a randomised controlled trial. BMJ 1998, 317:1177-80.
• [3]Hietanen P, Aro AR, Holli K, Absetz P: Information and communication in the context of a clinical trial. Eur J Cancer 2000, 36:2096-104.
• [4]Locock L, Smith L: Personal experiences of taking part in clinical trials – a qualitative study. Patient Educ Couns 2011, 84:303-9.
• [5]Emanuel EJ, Miller FG: The ethics of placebo-controlled clinical trials – a middle ground. N Engl J Med 2001, 345:915-9.
• [6]Millum J, Grady C: The ethics of placebo-controlled trials: methodological justifications. Contemp Clin Trials 2013, 36:510-4.
• [7]World Medical Association: Declaration of Helsinki – ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/ webcite
• [8]Rothman KJ, Michels KB: The continuing unethical use of placebo controls. N Engl J Med 1994, 331:394-8.
• [9]Bishop FL, Adams AE, Kaptchuk TJ, Lewith GT: Informed consent and placebo effects: a content analysis of information leaflets to identify what clinical trial participants are told about placebos. PLoS One 2012, 7(6):e39661. doi:10.1371/journal.pone.0039661
• [10]Lääkealan turvallisuus- ja kehittämiskeskuksen määräys: Kliiniset lääketutkimukset. http://www.fimea.fi/download/22302_Maarays_2-2012_kliiniset_laaketutkimukset.pdf webcite
• [11]Sosiaali- ja terveysministeriö. Lääketieteellinen tutkimuseettinen jaosto (TUKIJA). Muistilista eettisten toimikuntien jäsenille ja tutkijoille. http://www.tukija.fi/c/document_library/get_file?folderId=18753&name=DLFE-680.pdf webcite
• [12]Graneheim UH, Lundman B: Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today 2004, 24:105-12.
• [13]European Medicines Agency: Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/01/WC500100710.pdf webcite
• [14]Cameron P, Pond GR, Xu RY, Ellis PM, Goffin JR: A comparison of patient knowledge of clinical trials and trialist priorities. Curr Oncol 2013, 20:e193-205. doi:10.3747/co.20.1323
• [15]Ferguson PR: Information giving in clinical trials: the views of medical researchers. Bioethics 2003, 17:101-1.
• [16]Hereu P, Pérez E, Fuentes I, Vidal X, Suñé P, Arnau JM: Consent in clinical trials: what do patients know? Contemp Clin Trials 2010, 31:443-6.
• [17]Halpern SD, Ubel PA, Berlin JA, Townsend RR, Asch DA: Physicians’ preferences for active-controlled versus placebo-controlled trials of new antihypertensive drugs. J Gen Intern Med 2002, 17:689-95.
• [18]Roberts LW, Warner TD, Brody JL, Roberts B, Lauriello J, Lyketsos C: Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: Assessment of harm potential and factors influencing participation decisions. Am J Psychiat 2002, 159:573-84.
• [19]Kucia AM, Horowitz JD: Is informed consent to clinical trials an ‘upside selective’ process in acute coronary syndromes? Am Heart J 2000, 140:94-7.
• [20]Bertoli AM, Strusberg I, Fierro GA, Ramos M, Strusberg AM: Lack of correlation between satisfaction and knowledge in clinical trials participants: a pilot study. Contemp Clin Trials 2007, 28:730-6.
• [21]Bergenmar M, Molin C, Wilking N, Brandberg Y: Knowledge and understanding among cancer patients consenting to participate in clinical trials. Eur J Cancer 2008, 44:2627-33.
• [22]Kerr C, Robinson E, Stevens A, Braunholtz D, Edwards S, Lilford R: Randomisation in trials: do potential trial participants understand it and find it acceptable? J Med Ethics 2004, 30:80-4.
• [23]Madsen SM, Holm S, Davidsen B, Munkholm P, Schlichting P, Riis P: Ethical aspects of clinical trials: the attitudes of participants in two non-cancer trials. J Intern Med 2000, 248:463-74.
• [24]Madsen SM, Mirza MR, Holm S, Hilsted KL, Kampmann K, Riis P: Attitudes towards clinical research amongst participants and nonparticipants. J Intern Med 2002, 251:156-68.
• [25]Corbett F, Oldham J, Lilford R: Offering patients entry in clinical trials: preliminary study of the views of prospective participants. J Med Ethics 1996, 22:227-31.
• [26]Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller HJ: Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psy Clin N 2003, 253:22-8.